HC Wainwright Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

Omeros logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright reaffirmed its Buy rating on Omeros and set a $33 price target, implying 149.34% upside from the stock’s then-current price. Analysts’ consensus rating was Moderate Buy, with a $30.33 average target.
  • Omeros reported quarterly EPS of $0.06, beating the $0.02 estimate, but revenue of $35.93 million fell short of the $37.28 million consensus.
  • Shares fell $3.44 to $13.23 on Tuesday. Company insiders also sold a combined 100,906 shares over the prior quarter.
  • MarketBeat previews top five stocks to own in December.

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $33.00 price objective on the biopharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 149.34% from the company's current price.

Several other brokerages have also recently issued reports on OMER. Cantor Fitzgerald restated an "overweight" rating and issued a $22.00 price target on shares of Omeros in a research report on Wednesday, October 14th. Weiss Ratings upgraded shares of Omeros from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Finally, Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Omeros currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

Read Our Latest Stock Report on Omeros

Omeros Stock Performance

Shares of Omeros stock traded down $3.44 on Tuesday, hitting $13.23. The stock had a trading volume of 1,131,558 shares, compared to its average volume of 1,592,276. The stock has a 50 day moving average of $18.22 and a 200 day moving average of $13.76. Omeros has a twelve month low of $6.70 and a twelve month high of $21.24. The firm has a market capitalization of $958.08 million, a P/E ratio of 10.47 and a beta of 2.96.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The business had revenue of $35.93 million during the quarter, compared to the consensus estimate of $37.28 million. Equities analysts expect that Omeros will post -0.37 earnings per share for the current year.

Insider Activity

In other news, Director Arnold C. Hanish sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the transaction, the director owned 5,000 shares in the company, valued at approximately $94,750. The trade was a 66.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas J. Cable sold 15,000 shares of the company's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the sale, the director directly owned 35,067 shares in the company, valued at approximately $646,986.15. This represents a 29.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 100,906 shares of company stock worth $1,904,955. 10.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently bought and sold shares of OMER. BlackRock Inc. acquired a new position in shares of Omeros in the 2nd quarter valued at about $57,484,000. State Street Corp lifted its stake in Omeros by 20.9% in the second quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company's stock valued at $22,062,000 after buying an additional 400,331 shares during the period. Corient Private Wealth LP bought a new position in shares of Omeros during the 2nd quarter worth approximately $6,274,000. Goldman Sachs Group Inc. boosted its holdings in shares of Omeros by 151.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 395,032 shares of the biopharmaceutical company's stock worth $7,521,000 after buying an additional 238,024 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Omeros by 57.8% during the 1st quarter. Bank of America Corp DE now owns 204,805 shares of the biopharmaceutical company's stock worth $2,163,000 after buying an additional 74,997 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros News Roundup

These are some of the OMER news items that stood out recently:

  • Positive Sentiment: Omeros reported earnings of $0.06 per share, above analyst expectations. It also said YARTEMLEA generated $41.8 million in gross revenue in the quarter, highlighting demand for its approved TA-TMA treatment. Omeros third-quarter results
  • Neutral Sentiment: The company expects $5 million to $6 million of income from discontinued operations in the fourth quarter while continuing to build YARTEMLEA education and outpatient use. The outlook may help near-term results, though the article does not establish the longer-term impact. Q4 outlook and YARTEMLEA expansion
  • Negative Sentiment: Quarterly revenue was $35.9 million, below the roughly $37.3 million analyst estimate. Market coverage also highlighted a wider third-quarter loss, tempering the positive per-share earnings surprise and contributing to pressure on OMER shares. Report on Omeros's wider third-quarter loss

Omeros Company Profile

(Get Free Report)

Omeros Corporation NASDAQ: OMER is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

Further Reading

Analyst Recommendations for Omeros (NASDAQ:OMER)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Omeros Right Now?

Before you consider Omeros, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omeros wasn't on the list.

While Omeros currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines